IQWiG, Germany's Institute for Quality and Efficacy in Healthcare, says that the benefits of the hypolipidaemic combination product ezetimibe are not clear. The institute's report does not bode well for Merck & Co, which markets Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin).
http://www.scripintelligence.com/home/GBA-to-decide-on-future-of-Mercks-ezetimibe-after-German-assessment-sees-no-benefit-321152?
http://www.scripintelligence.com/home/GBA-to-decide-on-future-of-Mercks-ezetimibe-after-German-assessment-sees-no-benefit-321152?
No comments:
Post a Comment